Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.46 |
| ▸ | ADH1B | P00325 | 1/20 | 0.43 |
| ▸ | ADH1C | P00326 | 1/20 | 0.43 |
| ▸ | ADH1A | P07327 | 1/20 | 0.43 |
| ▸ | ADH4 | P08319 | 1/20 | 0.43 |
| ▸ | ADH7 | P40394 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6348875 | 1.00 | — | — | |
| SCHEMBL200216 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBGPR84SPHK1 | |
| SCHEMBL100862 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBGPR84SPHK1 | |
| SCHEMBL2201684 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBGPR84SPHK1 | |
| SCHEMBL201087 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBGPR84SPHK1 | |
| SCHEMBL2201024 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBGPR84SPHK1 | |
| SCHEMBL2201062 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBGPR84SPHK1 | |
| SCHEMBL21899376 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBGPR84SPHK1 | |
| SCHEMBL22407240 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBGPR84SPHK1 | |
| SCHEMBL26044 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBGPR84SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592351-B2 | Substituted imidazo[1,2-a]pyridine compounds and pharmaceutical preparations containing substituted imidazo[1,2-a]pyridine compounds | GRUENENTHAL GMBH (DE) | 2009-09-22 | — | — | US | claimed |
| US-20070099896-A1 | Substituted imidazo[1,2-a]pyridine compounds and pharmaceutical preparations containing substituted imidazo[1,2-a]pyridine compounds | GRUENENTHAL GMBH (DE) | 2007-05-03 | — | — | US | claimed |
| EP-1756105-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND DRUGS CONTAINING SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2007-02-28 | — | — | EP | claimed |
| WO-2005105798-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND DRUGS CONTAINING SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2005-11-10 | — | — | WO | claimed |
| JP-59110640-A | — | — | None | — | — | JP | disclosed |
| CN-118215651-A | Method for producing isocyanate compound, method for producing urethane compound, method for recovering amine compound, and isocyanate composition | 旭化成株式会社 | 2024-06-18 | — | — | CN | disclosed |
| CN-118201905-A | Cationic lipid | 武田药品工业株式会社 | 2024-06-14 | — | — | CN | disclosed |
| CN-113710367-B | Method for flotation of silicate-containing iron ore with cationic collector | 巴斯夫欧洲公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2024018762-A1 | PH-SENSITIVE CATIONIC LIPID AND LIPID NANOPARTICLE | 国立大学法人北海道大学 | 2024-01-25 | — | — | WO | disclosed |
| WO-2024018761-A1 | NEUTRAL LIPID AND LIPID NANOPARTICLE | 国立大学法人北海道大学 | 2024-01-25 | — | — | WO | disclosed |
| CN-114207210-B | Fiber treating agent for nonwoven fabric | 三吉油脂株式会社 | 2023-09-19 | — | — | CN | disclosed |
| CN-116685409-A | Method for flotation of silicate-containing iron ore | 巴斯夫欧洲公司 | 2023-09-01 | — | — | CN | disclosed |
| US-5120738-A | Cardiovascular disorders | FUJIREBIO INC. (JP) | 1992-06-09 | — | — | US | disclosed |
| EP-0421441-A2 | Pantothenic acid derivatives | FUJIREBIO INC. (JP) | 1991-04-10 | — | — | EP | disclosed |
| US-4798721-A | LATEX, WATER INSOLUBLE MONOMERS | KAO CORPORATION (JP) | 1989-01-17 | — | — | US | disclosed |
| US-4676915-A | Antistatic composition and detergent compositions containing antistatic components | COLGATE-PALMOLIVE COMPANY (US) | 1987-06-30 | — | — | US | disclosed |
| EP-0214626-A2 | Hair cosmetic composition | Kao Corporation (JP) | 1987-03-18 | — | — | EP | disclosed |
| US-4626429-A | Conditioning of hair with amides of trialkylacetic acids | COLGATE-PALMOLIVE COMPANY (US) | 1986-12-02 | — | — | US | disclosed |
| JP-S59110640-A | 2-METHYLHEPTADECYL GLYCERYL ETHER | KAO CORP | 1984-06-26 | — | — | JP | disclosed |
| US-4331683-A | SENSITIZATION, ANTIALLERGENS | PFIZER INC. (US) | 1982-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099896-A1 | Substituted imidazo[1,2-a]pyridine compounds and pharmaceutical preparations containing substituted imidazo[1,2-a]pyridine compounds | GIPR, CHUK, ITPA | OPRM1 1842/4885TSHR 1545/4885THRB 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.